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TUBERCULOSIS (TBC) is characterized by a complex im-
mune response which parallels the clinical course of the
disease. In this respect, acquired resistance, delayed hyper-
sensitivity reaction and anergy are the main types of
immune reactivity to mycobacterial antigens. In view of
the presence of nonspecific and specific immune deficits
in TBC patients, a clinical trial was carried out in a group
of 20 individuals with active pulmonary TBC by oral
administration of acetyl-L-carnitine (ALC). This drug,
which has been shown to possess immunomodulating
activities, was able to upregulate the T-dependent anti-
bacterial activity in TBC patients after 30 days’ treatment,
while the same activity decreased in patients receiving
placebo only. On the other hand, ALC did not modify
serum levels of tumour necrosis factor-cx, in the same
individuals. This cytokine plays a detrimental rather than
beneficial role in TBC pathogenesis. In the light of these
data, ALC seems to be a powerful immunomodulator in
the course of Mycobacterium tuberculosis infection and
other mycobacteriosis.
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Introduction
Tuberculosis (TBC) is a pathological process
characterized by a broad spectrum of immunologi-
cal responses which correlate with the clinical
course of the disease.1
-.3 In TBC, immune
responsiveness depends on three basic mechanisms"
(1) acquired cellular resistance; (2) delayed type
1--3 hypersensitivity (DTH); and (3) anergy.
.Acquired cellular resistance is a protective
mechanism in which specific T-cells are activated
by macrophages, the so-called antigen presenting
cells. 4 With special reference to mycobacterial
antigens, mainly proteins, e.g. heat shock proteins
(HSP), are presented by macrophages to both
human and murine + cells. On the other
hand, murine CD4+ and CD8 + cells seem to
participate to acquired resistance, even if others
claim that only CD4+ cells are the major protective
subset in long-term protective studies,l In humans,
recent studies have pointed out that CD4+ cells
kill monocytes which contain mycobacteria regard-
less of the T-helper (h)l-Th2 subset distinction and
of the HSP recognition.
l
DTH is a detrimental reaction dependent on the
sensitization of specific lymphocytes by myco-
bacterial antigens and usually leads to granuloma
formation.
13 Granuloma, which consists of an
accumulation of macrophages, may undergo either
a protective evolution with microorganism neu-
tralization or a caseification with tissue damage.
3
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In the phase of macrophage accumulation, two
inflammatory cytokines (CKs), namely the mono-
cyte chemotactic protein-1 (MCP-1) and the
macrophage inhibiting factor play an important
role.
1-3 In the phase of tubercular granuloma
evolution interferon-2 (IFN-2) and interleukin-2
(IL-2) are protective, 12’13 while tumour necrosis
factor-z (TNFo) is mostly involved in granuloma
destruction.
14
With special reference to TNFoq it has been
reported that lipoarabinornannan (LAM) from the
M. tuberculosis cell wall is responsible for the
production of this CK,
15 as is also confirmed by
studies on LAM-induced transcription of mRNA
for several CKs, even including TNFo.
l Further-
more, by analogy with other intracellular infections
(e.g.M. avium and M. bovis infections, listerosis,
toxoplasmosis and trypanosomiasis)
17 TNFz should
also play a protective role in the case of M.
tuberculosis infection. However, according to Filley
and Rook
18 virulent TBC strains produce a factor
which alters the normal function of TNFo,
rendering it toxic to host tissue. Therefore, many
clinical and laboratory findings in TBC patients may
be ascribed to TNFo release, such as fever, weight
loss, necrosis, intravascular coagulation and acute
phase protein release.
19 On the other hand, data of
Barnes et al.
20 support a protective role for TNFz
in the course of pleuritis, which usually resolves in
the absence of therapy. Moreover, Takashima et al.21
report a reduction ofTNF0 in patients with chronic
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TBC. Taken together, these findings attribute a
noxious role to TNF0 in the course of TBC, while
beneficial effects of this CK may arise when it is
moderately produced or locally released as in the
case of pleural effusion.
Anergy is a clinical condition of depressed
immune function, as observed in patients with
advanced refractory TBC.
1--3 Several mechanisms
have been postulated for explaining the immuno-
suppression in TBC patients. In this respect,
bacterial cell wall components, e.g. D-arabino-D-
galactan, can downregulate Fc receptor (R) function
on cell membranes by circulating in the form of
immunocomplexes.
22 Furthermore, prostaglandin
E2 release by monocytes may reduce II,-2
production and decrease expression of IL-2 R.
2
Another immunosuppressive agent is represented
by IL-1, which inhibits T-lymphocyte proliferation
by protein purified derivative (PPD) when
produced in exaggerated amounts.
4 Finally, a
25 kDa glycoprotein derived from M. tuberculosis
has been shown to inhibit phagocytic functions.
25
These data emphasize that a plethora of
suppressive factors may be involved in the
depression ofimmune response in TBC patients and
their recognition is important for the establishment
of therapeutic strategies.
Monitoring of the Immune Status in
Patients with TBC
Until now, many studies have been focused on
T-lymphocyte functions in TBC individuals and, in
particular, T-cell response to mitogens and antigens
has been evaluated. In contrast, less information is
available on polymorphonuclear cell (PMN) and
monocyte functions, and on B-cell activity.
In a recent study, a group of 14 patients with
TBC (seven individuals with acute disease and
seven individuals with chronic disease) have been
evaluated in terms of phagocytic and B-cell
functions.
% PMN and monocyte activities were
assessed by determining their chemotactic capacity
and ability to phagocytose Candida albicans. At the
same time, the release of two inflammatory CKs,
leucocyte inhibiting factor (LIF) and MCP-1 was
determined Results show that chemotaxis, phago-
cytosis and killing were reduced regardless of the
disease status.
26 The impaired release of LIF and
MCP-1 could also explain the altered phagocytic
activity.
Assessment of B-cell responsiveness was per-
formed by evaluating in vitro antibody synthesis in
a plaque-forming cell system, using pokeweed
mitogen (PWM) as a polyclonal activator and PPD
as a specific antigen. In patients with acute TBC,
anti-PPD antibody response was significantly
augmented, while in patients with acute and chronic
TBC PWM-induced antibody production fell
within normal values.
26 These last results are in
accordance with findings of others who detected
elevated IgG serum levels to PPD in acute TBC.
27
Moreover, a strict correlation was found between
ELISA positivity for anti-PPD IgG antibody and
TBC diagnosis.
28 In chronic patients the lack of
anti-PPD antibody response may depend on B-cell
immunosuppression, despite an elevated frequency
of B-cells.
The bulk of the above data support the usefulness
of monitoring different compartments of the
immune system in TBC patients, since deficits in
these individuals seem to be more vast than
expected.
Oral Administration of
AcetyI-L-carnitine in Patients with
Active Pulmonary Tuberculosis
Much evidence supports the concept that the
immune response plays an important role in the
pathogenesis of TBC. Quite interestingly, the
authors’ previous results emphasize that even
patients in the acute phase exhibit multiple deficits
of either nonspecific or specific immunity. Now, the
question arises concerning the opportunity to
immunomodulate these subjects in order to avoid
superimposition of other infections (e.g. historic-
ally, measles; nowadays, HIV infection). However,
the risk exists that classical biological response
modifiers (BRM), which enhance immune response
via CK release,
29 may trigger detrimental DHRs for
the host. In this framework, it was reasoned that a
putative BRM, which may increase the metabolic
performance of immune cells rather than inducing
release of noxious mediators, should be more
appropriate for treating TBC subjects.
Just recently, ALC, a substance which is actively
involved in either the transport and oxidation of
fatty acids into mitochondria, or in the production
and incorporation of their unsaturated forms into
3O membrane phospholipids, has been shown to
possess immunoregulatory properties. Studies in
this direction have, in fact, demonstrated, that ALC
reduced macrophage and lymphocyte function
decline in aged rats
1 and enhanced mitogen-induced
lymphocyte proliferation in the elderly.
2 In AIDS
subjects treated with ALC an improvement of
immunocompetence was found and this correlates
with the reduced levels of carnitine detected in these
patients.
-4
On this basis, 20 subjects with active pulmonary
TBC vere enrolled in a double blind, randomized,
co.trolled parallel study.
35 Ten patients were
treated orally with 2 g ALC/day (Nicetile, Sigma-
Tau, Pomezia, Italy) for 30 days. The control group
received placebo only. Two main immune para-
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meters were followed up at day 0 and day 30,
namely the antibacterial activity and TNFo serum
levels.
Antibacterial activity is a T-cell function
dependent on CD4+ and CD8 + cell activity which
represents a good index of the host resistance
against pathogens, even including M. tuberculosis.
36
This activity was depressed in both groups of
patients at time 0, but, while it increased in the
ALC-treated individuals, it decreased in the subjects
receiving placebo only. Several hypotheses can be
formulated to explain the immunomodulating
activities of AI,C: (1) ALC may act by supplementa-
tion of energy to lymphocytes via ATP; (2)
chemotherapy may impair lymphocytic functions in
these patients37’38 and ALe eventually potentiates
the reduced antibacterial activity and/or prevents
iatrogenic immunosuppression; or (3) AI,C can
modulate the hypothalamus-pituitary-adrenal axis
with release of enhancing neurohormones and
neuropeptides.
39
As far as determination of serum levels of TNFcz
is concerned, no differences were seen between the
two groups, since mean values of this CK fluctuated
within normal ranges before and after treatment.
However, in three cases within the ALC-treated
gr()up and in two cases within the placebo group
TNFo levels increased by day 30. Although
anamnesis, clinical examination, disease and state
and other related blood parameters were taken into
consideration, a reasonable explanation for under--
standing the above finding was not achieved.-It is
noteworthy that this present data confirms that
reported by Rook et al.,
19 who also found normal
serum levels of TNF0 in TBC patients. In this
c(mtext, to extend our data further, studies will
evaluate in vitro TNF release from I,AM-
stimulated monocytes in AI,C-treated TBC patients.
In fact, detection of TNF0 in serum can be
prevented by the presence of inhibitors found in
TBC and sarcoidosis.
4
Therapeutic Application of
AcetyI-L-carnitine in
Mycobacteriosis
Tuberculosis and leprosy are the two major
mycobacterial infections in which a deficit of Th
cells has been recognized, mostly in terms of
release of protective CKs, such as II,-2 and
IFN_7.1
3,12,13,41 43 On the other hand, according to
Grau et al. 44 TNFo may cause both protection and
clinical manifestations in mycobacterial disease and
pathology should be interpreted as the consequence
of the protective mechanism. Therefore, a pharma-
cy)logical modulation of the immune response in
mycobacteriosis should be applied to the T-cell
compartment, excluding the monocyte-macro-
phage system whose products, e.g. IL-1 and TNFo,
are more detrimental than beneficial.24’44
The authors’ data indicate that ALC may
represent a suitable BRM for treating mycobacteri-
osis, since it increases T-cell dependent antibacterial
activity without effect on in vivo TNFo production
in the affected patients. In this respect, the
improvement of clinical and immunological
findings observed in ALC-treated AIDS patients
33
indirectly confirms that this compound acts on
lymphocytes but not on cellular sources of TNFo.
In fact, several papers support the prominent role
of TNFo as the cofactor in the triggering and
worsening of HIV infection.
45 48
Finally, even if these preliminary results seem to
support the immunomodulating capacities of AI,C,
long-term studies and monitoring of additional
immune parameters are needed on a broader sample
of the population affected by mycobacterial disease.
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